Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Lymphoma 9Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Large B-Cell, Diffuse 5Neoplasm Metastasis 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Follicular 4Hodgkin Disease 4Sarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Intraocular Lymphoma 2Immunoblastic Lymphadenopathy 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 2 × Bevacizumab × Lymphoid × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡